ABBN.SW: $86.68 ▲ 0.58 (0.67%)ASML.AS: $1,577.20 ▲ 16.40 (1.05%)ENR.DE: $159.30 ▼ -3.20 (-1.97%)GLEN.L: $521.80 ▼ -13.50 (-2.52%)IFX.DE: $81.02 ▲ 0.46 (0.57%)NOKIA.HE: $12.35 ▲ 0.35 (2.92%)RIO.L: $7,198.00 ▼ -66.00 (-0.91%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

TC Biopharm (Holdings) Plc

TCBP - NASDAQ

Identifiants & Marche

Ticker TCBP
ISIN US87807D4007
CIK 0001872812
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays GB
Siege N/A
Fondee N/A
Site Web Lien

Description

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Voir l'evolution du cours Retour